>

Orphazyme Volatility

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:4em;padding-top: 25px;;'>OR</div>
ORPHA -- Denmark Stock  

DKK 90.80  7.70  7.82%

Macroaxis considers Orphazyme not too volatile given 3 months investment horizon. Orphazyme AS maintains Sharpe Ratio (i.e. Efficiency) of 0.0731, which implies the corporation had 0.0731% of return per unit of risk over the last 3 months. Our philosophy towards forecasting volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for Orphazyme AS, which you can use to evaluate future volatility of the company. Please employ Orphazyme AS Risk Adjusted Performance of 0.3336, Coefficient Of Variation of 1152.35 and Semi Deviation of 6.56 to confirm if our risk estimates are consistent with your expectations.
View Volatility For
Refresh
Orphazyme Stock volatility depicts how high the prices fluctuate around the mean (or its average) price. In other words, it is a statistical measure of the distribution of Orphazyme daily returns, and it is calculated using variance and standard deviation. We also use Orphazyme's beta, its sensitivity to the market, as well as its odds of financial distress to provide a more practical estimation of Orphazyme volatility.

90 Days Market Risk

Not too volatile

Chance of Distress

Below Average

90 Days Economic Sensitivity

Moves indifferently to market moves

Orphazyme Market Sensitivity

As returns on market increase, returns on owning Orphazyme are expected to decrease at a much smaller rate. During bear market, Orphazyme is likely to outperform the market.
3 Months Beta |Analyze Orphazyme AS Demand Trend
Check current 30 days Orphazyme correlation with market (DOW)
β = -0.0316

Orphazyme Central Daily Price Deviation

Orphazyme AS Technical Analysis

Transformation
The output start index for this execution was zero with a total number of output elements of sixty-one. The Median Price line plots median indexes of Orphazyme AS price series. View also all equity analysis or get more info about median price price transform indicator.

Orphazyme Projected Return Density Against Market

Assuming 30 trading days horizon, Orphazyme AS has beta of -0.0316 . This implies as returns on benchmark increase, returns on holding Orphazyme are expected to decrease at a much smaller rate. During bear market, however, Orphazyme AS is likely to outperform the market. Moreover, The company has an alpha of 0.5129 implying that it can potentially generate 0.5129% excess return over DOW after adjusting for the inherited market risk (beta).
 Predicted Return Density 
    
  Returns 
Assuming 30 trading days horizon, the coefficient of variation of Orphazyme is 1367.58. The daily returns are destributed with a variance of 42.99 and standard deviation of 6.56. The mean deviation of Orphazyme AS is currently at 4.72. For similar time horizon, the selected benchmark (DOW) has volatility of 3.8
α
Alpha over DOW
=0.51
β
Beta against DOW=0.03
σ
Overall volatility
=6.56
Ir
Information ratio =0.15

Orphazyme Return Volatility

the company accepts 6.5565% volatility on return distribution over the 30 days horizon. the entity inherits 3.9887% risk (volatility on return distribution) over the 30 days horizon.
 Performance (%) 
    
  Timeline 

Orphazyme Investment Opportunity

Orphazyme AS has a volatility of 6.56 and is 1.64 times more volatile than DOW. 58  of all equities and portfolios are less risky than Orphazyme. Compared to the overall equity markets, volatility of historical daily returns of Orphazyme AS is higher than 58 () of all global equities and portfolios over the last 30 days. Use Orphazyme AS to protect your portfolios against small markets fluctuations. The stock experiences very speculative upward sentiment. Check odds of Orphazyme to be traded at kr86.26 in 30 days. . As returns on market increase, returns on owning Orphazyme are expected to decrease at a much smaller rate. During bear market, Orphazyme is likely to outperform the market.

Orphazyme correlation with market

correlation synergy
Good diversification
Overlapping area represents the amount of risk that can be diversified away by holding Orphazyme AS and equity matching DJI index in the same portfolio.

Orphazyme Current Risk Indicators

Orphazyme Suggested Diversification Pairs

Please check Your Equity Center. Please also try Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page